

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2753890

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BAYLOR COLLEGE OF MEDICINE	05/21/2013
RECEIVING PARTY DATA	
Name:	PACIFIC ARROW LIMITED
Street Address:	SUITE 1222, 12/F, LEIGHTON CENTRE
Internal Address:	77 LEIGHTON ROAD, CAUSEWAY BAY
City:	HONG KONG
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14020099
CORRESPONDENCE DATA	
Fax Number:	(718)357-8615
Phone:	(718) 799-1000
Email:	chank@kitchanlaw.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	LAW OFFICES OF ALBERT WAI-KIT CHAN, PLLC
Address Line 1:	141-07 20TH AVENUE
Address Line 2:	WORLD PLAZ, SUITE 604
Address Line 4:	WHITESTONE, NEW YORK 11357
ATTORNEY DOCKET NUMBER:	1488-B1-PCT-US
NAME OF SUBMITTER:	ALBERT WAI-KIT CHAN
Signature:	/Albert Wai-Kit Chan/
Date:	03/05/2014
Total Attachments: 3 source=2013 Baylor Assignments (signed by Baylor)#page1.tif source=2013 Baylor Assignments (signed by Baylor)#page2.tif source=2013 Baylor Assignments (signed by Baylor)#page3.tif	

ASSIGNMENT

This Assignment Agreement (hereinafter called "Agreement"), to be effective on the last date of execution hereof (hereinafter called "Agreement Date"), is by and between BAYLOR COLLEGE OF MEDICINE (hereinafter called "BAYLOR"), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Houston, Texas 77030, USA, and PACIFIC ARROW LIMITED, a corporation of the British Virgin Islands having a place of correspondence at Suite 1222, 12/F., Leighton Centre, 77 Leighton Road, Causeway Bay, Hong Kong, China, and its Affiliates, successors and assignees (hereinafter, collectively referred to as "COMPANY").

1. DEFINITIONS AS USED HEREIN

- 1.1 The term "Affiliates" shall mean any corporation, partnership, joint venture or other entity of which the common stock or other equity ownership thereof is twenty five percent (25%) or more owned by COMPANY.
- 1.2 The term "Patent Rights" shall mean applications for Letters Patent in the United States and the corresponding foreign patent applications identified on Schedule A hereto as attached, which were developed by Pui-Kwong Chan, Ph.D., an employee of BAYLOR, alone, or with employee(s) of COMPANY, the respective inventions described therein, and all other pending United States patent applications and any and all divisions, reissues, re-examinations, renewals, continuations, continuation-in-part, and extensions thereof, and all other counterpart, pending or issued patents in all other countries. "Patent Rights" shall also include but is not limited to all other rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of intellectual property.

2. GRANT OF ASSIGNMENT

As per paragraph 9 of the Testing Contract dated October 9, 2003, and all subsequent amendments, by and between BAYLOR and Data Prospect Company Limited, which has assigned all of its rights to COMPANY, and by and between BAYLOR and COMPANY, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by BAYLOR, BAYLOR does hereby SELL, ASSIGN and

CONVEY unto COMPANY, its successors and assigns all of its undivided right, title and interest throughout the world in and to the Patent Rights.

BAYLOR hereby agrees to execute upon reasonable request and at COMPANY's expense any other lawful documents and likewise to perform any other lawful acts which may be necessary to fully secure the Patent Rights to the COMPANY, its successors, assigns, and legal representatives, including the execution of applications for patent in foreign countries, and the execution of substitution, reissue, divisional, or continuation application and/or preliminary or other statements and the giving of testimony in any interference or other proceeding in which the Patent Rights may be involved; and BAYLOR further hereby authorizes the COMPANY or its attorneys or agents to insert the correct serial number and filing date into this assignment, including any pending United States patent applications or other counterpart, pending or issued patents in all other countries which claim or disclose compositions and/or compounds isolated from the inventions disclosed by the applications listed herein as **Schedule A**, if appropriate.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their duly authorized officers and representatives on the respective dates shown below, but effective as of the Agreement Date.

PACIFIC ARROW LIMITED

BAYLOR COLLEGE OF MEDICINE

Name: _____

Name: Adam Kuspa

Adam Kuspa, Ph.D.

Title: _____

Title: Sr. Vice President, Research

Date: _____

Date: 5/21/13

Witness: _____

(signature)

Witness: _____

(signature)

(printed name of witness)

(printed name of witness)

(address of witness)

(address of witness)

APPROVED AS TO FORM
Office of the General Counsel
Baylor College of Medicine
By [Signature]

Schedule A

Application No.	Title	Filing Date	Status	Dkt. #
13/841,053	Methods and Compounds for Modulating the Secretion or Expression of Adhesion Proteins or Angiopoietins of Cells	March 15, 2013	Pending	804-HB-US
PCT/US2007/077273	Anti-Tumor Compounds for Inhibiting Cancer Growth	August 30, 2007	Expired	804-M-PCT
PCT/US2008/002086	Blocking the Migration or Metastasis of Cancer Cells by Affecting Adhesion Proteins and the Uses of New Compounds Thereof	February 15, 2008	Expired	1188-ALA-PCT
12/856,322	Novel Triterpenes for Modulating Gene Expression and Cell Membrane, and as Antiprotozoal Agents	August 13, 2010	Pending	1188-DA-PCT-US
PCT/US2011/044233	New Compounds for Treating Cancer and Other Diseases	July 15, 2011	Expired	1488-B-PCT
PCT/US2012/046716	New Natural and Synthetic Compounds for Treating Cancer and Other Diseases	July 13, 2012	Pending	1488-C-PCT